Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Transfer Hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel catalytic transfer hydrogenation method for Ticagrelor intermediate. Reduces cost and toxicity compared to borane reduction. High ee value.
Patent CN109574797A details water-based reduction for luliconazole intermediate. Offers high yield and purity with recyclable catalysts for cost-effective pharmaceutical manufacturing supply chains.
Novel N-monosulfonated chiral diamines enable efficient aqueous phase asymmetric hydrogenation, reducing solvent waste and costs for API intermediates.
Patent CN115803318A details an enantioselective route for high-purity tetrahydroquinoline intermediates, offering significant cost and supply chain advantages for pharmaceutical manufacturing.
Patent CN115448813B details a manganese-catalyzed route for Crizotinib intermediates. Achieves 95% ee with reduced costs and scalable mild conditions for global supply chains.
Patent CN117003651B breakthrough. Safer transfer hydrogenation. Cost reduction in pharma intermediate manufacturing. High-purity L-epinephrine production.
Patent CN103415524B details stereoselective reduction for dorzolamide intermediates. Offers supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN1759097A details a safer process for PDF inhibitor intermediates using specific beta-lactams and selective debenzylation, offering significant cost reduction in pharmaceutical intermediate manufacturing.
Patent CN115819387A details a novel Ru-catalyzed route for S-Pro-Xylane, offering high purity and safety for cosmetic manufacturing supply chains.
Patent CN105061126B reveals water-based rhodium catalysis for high-purity pharmaceutical intermediates. Achieve significant cost reduction and supply chain reliability.
Patent CN1360574A reveals a scalable route for tricyclic aminoalcohol derivatives using Ru-catalysis, offering cost reduction and high purity for pharmaceutical manufacturing.
Patent CN1360574A details a novel route for tricyclic aminoalcohol derivatives featuring asymmetric reduction. This process offers significant cost reduction and improved supply chain reliability for pharmaceutical manufacturing.
Discover the advanced enantioselective process for HMG-CoA inhibitors described in CN1636004A. Achieve high purity statin intermediates with reduced waste and scalable catalytic methods.
Patent CN1636004A details a novel asymmetric transfer hydrogenation route for HMG-CoA inhibitors. Achieve high purity statin intermediates with reduced waste and scalable manufacturing processes.
Patent CN102119165A introduces stable chiral iridium catalysts for asymmetric transfer hydrogenation in water, offering safer and greener pharmaceutical intermediate manufacturing.
Novel aqueous chiral iridium catalyst enables safe, high-yield asymmetric transfer hydrogenation for pharmaceutical intermediates with superior stability.
Patent CN1968927B details a novel Ru-catalyzed route for high-purity quinoline intermediates used in bronchodilators, offering significant cost reduction in API manufacturing.
Patent CN1445224A details a novel Ru-catalyzed asymmetric transfer hydrogenation process for high-purity pharmaceutical intermediates, offering significant cost and supply chain advantages.
Patent CN106938995B details asymmetric synthesis for bepotastine besilate. This method offers significant cost reduction and supply chain reliability for ophthalmic drug intermediate manufacturing partners.
Patent CN110526944A reveals high-efficiency Ru catalyst for asymmetric transfer hydrogenation, offering cost reduction and supply reliability.